Resources
CAR T Academy Resources
Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations
Kai Rejeski, Marion Subklewe, Mahmoud Aljurf, Emmanuel Bachy, Adriana Balduzzi, Pere Barba, Benedetto Bruno et al.
07.09.2023
Journal (Date):
Blood (2023)
Abstract Excerpt:
“We propose ICAHT as a novel toxicity category following immune effector cell therapy, provide a framework for its grading, review literature on risk factors, and outline expert recommendations for the diagnostic work-up and short- and long-term management.”
How I treat cytopenia after CAR T-cell therapy
Tania Jain, Timothy S. Olson, Frederick L. Locke
18.05.2023
Journal (Date):
Blood (2023)
Abstract Excerpt:
“Increasing use of CAR-T has unveiled diverse toxicities warranting specific recognition and management. Here we provide our approach, including workup and management strategies, for cytopenias after CAR-T.”
View DocumentTransplant-ineligible but chimeric antigen receptor T cells eligible: a real and relevant population
Samuel Vic, Jean Lemoine, Philippe Armand,
François Lemonnier, Roch Houot
24.09.2022
Journal (Date):
European Journal of Cancer (2022)
Abstract Excerpt:
“As the relative role of ASCT and CAR T-cells evolves, recognizing and defining this population may be increasingly relevant. Here, we review criteria which may help identify this 'ASCT-ineligible but CAR T-cells eligible' population of patients.”
View DocumentRisk assessment of potential CAR T candidates receiving a covalent BTK inhibitor for relapsed/refractory disease (Addendum to British Society for Haematology Guideline for the management of MCL, 2018)
Maeve A O'Reilly, Robin Sanderson, William Wilson, Sunil Iyengar, Jonathan Lambert, Rory McCulloch, Toby A Eyre;
BSH Guidelines Committee Haemato-oncology Task Force
27.07.2022
Journal (Date):
British Journal of Haematology (2022)
Abstract Excerpt:
“The advent of CAR T -cell therapy at third-line has prompted this addendum, the focus of which is to provide additional guidance for haematologists on the selection, investigation and surveillance of MCL patients considered potential candidates for future CAR T-cell therapy.”
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
Jason Westin and Laurie Sehn
05.05.2022
Journal (Date):
Blood (2022)
Abstract Excerpt:
“In this review, we interpret the design and results of 3 randomized phase 3 trials comparing CAR T-cell therapy and ASCT and their implications for CAR T-cell therapy as a potential new standard of care for second-line treatment in appropriate patients with refractory or early relapsing LBCL.”
View DocumentLymphoma Canada R/R DLBCL Guidelines
Dr. Mona Shafey, Dr. Kerry J. Savage, Dr. Pamela Skrabek, Dr. Mahmoud Elsawy, Dr. Mark Bosch, Dr. John Kuruvilla
01.09.2021
About:
Led by Lymphoma Canada, a group of experts from across Canada developed a national evidence-based treatment guideline to provide healthcare professionals with clear guidelines and best practices for the management of relapsed/refractory DLBCL.
View DocumentCAR T Therapy Learning Resources for Patients from Princess Margaret
Princess Margaret Cancer Classes
Online learning modules on CAR T therapy developed by Princess Margaret Cancer Centre for patients, caregivers, and family. These modules were co-created by patients and healthcare providers. Module topics include:
• Learn about CAR T-cell therapy
• Prepare for CAR T-cell therapy
• What to expect during T-cell collection
• Finalizing the CAR T-cell therapy plan
• What to expect during CAR T-cell therapy
• Follow-up after CAR T-cell therapy
• Learn about the role of caregivers
• Take care of your emotions
